- 03:22 PM Sell Mahindra Satyam: Sandeep Wagle
- 03:16 PM Suzlon, SCI, Delhi Int'l Airport may raise funds v...
- 03:15 PM GAIL India touches a 52-week high
- 03:14 PM Satyam says no out-of-court settlement with credit...
- 03:12 PM F&O Check: BPCL up 6%, adds 5.5 lakh shares in OI
- 03:08 PM Wal-Mart: No plans to invest in retail stores in I...
- 03:08 PM Gati to explore options to restructure biz; stk do...
- 03:00 PM Valecha Engg to consider fund raising; stk down
- 02:54 PM Rupee has support at 46.35: Comm Trendz
- 02:53 PM Auto sector growth to push up demand for rubber



Glenmark Pharmaceuticals Ltd [Glenmark], a research-based company headquartered in Mumbai (India) received US FDA approval to market Pravastatin Sodium oral tablets 10 mg, 20 mg and 40 mg, a generic version of Bristol Myers Squibb brand Pravachol that has annual sales of over USD 861 million. Glenmark is manufacturing the finished dose formulation at its USFDA approved manufacturing facility in Goa, India. Glenmark’s US subsidiary, Glenmark Pharmaceuticals Inc., USA [GPI] is responsible for marketing the product in the US and will commence supplies of the drug to customers immediately.
In the preceding month, Glenmark also received US FDA approval to market Naproxen Sodium oral tablets EQ 250 mg and 500 mg base, a generic version of Roche’s brand Anaprox and Naproxen oral tablets 250 mg, 375 mg and 500 mg, a generic version of Hoffmann-La Roche AG brand Naprosyn. The drugs have annual sales of USD 13 million and USD 53 million respectively. These drugs are also manufactured at Glenmark’s Goa facility and will be marketed in the US by GPI.
With these approvals, Glenmark’s subsidiary GPI will have 15 generic products in the US market. The Company has over 35 ANDAs undergoing US FDA approval process/launch.
Sourced From: Glenmark Pharmaceuticals Limited
|
|
Business
Business News | Economy | Earnings | BSE NSE Notices
General News
Current Affairs | Politics | World News | Sports | Entertainment
Corporate Strategy
Management | Advertising | Marketing | Legal
Personal Finance
Tax | Insurance | Credit Cards | Loans | Property | Retirement | Investment Help | Financial Planning | Fixed Income
Markets
Local Market | Global Market | Market Cues | Analysis | Expert & FII outlook | Brokerage Recomendation
Stocks
Stocks in News | Expert Advice | ADRs & GDRs | IPO
Mutual Funds
News | Advice | MF Analysis | Fund Managers Views
Lifestyle
Travel | Wellness | Technology | Auto| Books
-
Most Read
-
Most Viewed
- 10 Companies that FIIs love
- 10 companies that MF managers love
- Sudarshan Sukhani's top five picks for today's trade

- Ganeshaspeaks: Market prediction for Nov 25
- Expert sector picks to power your portfolio ahead

- Ex-bonus, RIL will see correction: SP Tulsian

- Mah Satyam looks at out-of-court settlement with creditors
- Mitesh Thacker's top 5 picks for trade today

- Mkts to remain strong; bet on midcaps: Ramesh Damani
- Will ITC dream run continue beyond FY10?

- Auto sector growth to push up demand for rubber
Source: Business Line
- High networth individuals see glitter in commodities
Source: Business Line
- Tatas may launch electric Indica by early 2011
Source: Business Line
- CBI unearths additional fraud of Rs4739cr in Satyam
Source: Business Line










